While further investigation with an expanded sample size is needed, these findings suggest that anti-PD-1 therapy may induce downregulation of HLA class I expression on tumor cells through the TGF-β pathway in the TIME of unresectable advanced or recurrent G/GEJ cancer. Here, TGFB1 is linked to neoplasm.